Explore

TrendlineTrendline
Global Arrayed CRISPR Screening Market Projected to Reach $3.43 Billion by 2030 Amidst Precision Drug Discovery Demand

Global Arrayed CRISPR Screening Market Projected to Reach $3.43 Billion by 2030 Amidst Precision Drug Discovery Demand

Global Arrayed CRISPR Screening Market Projected to Reach $3.43 Billion by 2030 Amidst Precision Drug Discovery Demand
Rapid ReadRapid Read
New England Biolabs and Mammoth Biosciences Partner to Advance CRISPR-Based Diagnostic Assays

New England Biolabs and Mammoth Biosciences Partner to Advance CRISPR-Based Diagnostic Assays

New England Biolabs (NEB) and Mammoth Biosciences have announced a global licensing agreement and the commercial launch of MB-CasFire™. This collaboration aims to accelerate the development of isothermal amplification-based assays. Under the agreement, NEB will manufacture and globally distribute Mammoth Biosciences' proprietary CRISPR enzyme. MB-CasFire™ is an engineered, thermostable Type V CRISPR nuclease that utilizes a guide RNA (gRNA) for target recognition. Its broad temperature activity range allows for direct coupling with isothermal amplification methods, such as loop-mediated isothermal amplification (LAMP) at 50-65°C and recombinase polymerase amplification (RPA) at 37-42°C. This integration simplifies assay architecture by combining amplification and CRISPR-based reporter cleavage into a single reaction, eliminating the need for multiple temperature incubation or component addition steps. The product is currently available for Research Use Only (RUO), providing researchers and diagnostics deve...
Rapid ReadRapid Read
UC San Diego's Center for Microbiome Innovation Partners with Oxford Nanopore Technologies to Advance Research

UC San Diego's Center for Microbiome Innovation Partners with Oxford Nanopore Technologies to Advance Research

The University of California San Diego (UC San Diego) Center for Microbiome Innovation (CMI) has announced a new partnership with Oxford Nanopore Technologies, integrating the latter into CMI's industry partner program. This collaboration aims to accelerate microbiome research through the use of Oxford Nanopore's real-time, long-read sequencing technologies. The PromethION 24 sequencing platform from Oxford Nanopore will be introduced into CMI's collaboratory at Franklin Antonio Hall, enhancing CMI's existing technological capabilities with high-throughput, long-read sequencing. CMI is also working towards becoming a designated Sequencing Service Provider on Oxford Nanopore Technologies' platforms, which will allow it to offer validated nanopore sequencing services to the broader UC San Diego research community and beyond. This partnership is expected to provide technical training and support to CMI's team, enabling students and researchers to leverage this advanced technology for their work.
Rapid ReadRapid Read
Global Genetic Testing Market Projected to Reach $26.4 Billion by 2030 Amidst Personalized Medicine Demand

Global Genetic Testing Market Projected to Reach $26.4 Billion by 2030 Amidst Personalized Medicine Demand

The global genetic testing market, valued at US$15 billion in 2024, is projected to grow to US$26.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.9%. This expansion is driven by increasing demand for personalized medicine, a rise in genetic disorders, broader application of genomic testing in oncology, and continuous advancements in sequencing technologies and data analytics. Genetic testing is expanding its role across various medical fields, including cancer care, cardiovascular medicine, rare disease diagnosis, prenatal and newborn screening, carrier screening, pharmacogenomics, and predictive testing. Personalized medicine is a significant catalyst, as healthcare providers increasingly utilize genomic information to select therapies, assess treatment responses, and mitigate adverse effects. Direct-to-consumer genetic testing is also contributing to market growth by enhancing public awareness and accessibility. Government funding, private investment, clinical research, and produc...
TrendlineTrendline
Vizgen Establishes New Business Unit, Velocity Lab, to Advance AI-Powered Spatial Biology Research

Vizgen Establishes New Business Unit, Velocity Lab, to Advance AI-Powered Spatial Biology Research

Vizgen Establishes New Business Unit, Velocity Lab, to Advance AI-Powered Spatial Biology Research
Rapid ReadRapid Read
GeneSPOT Computational Framework Introduced to Map Spatial Gene Relationships and Dynamics in Tissues

GeneSPOT Computational Framework Introduced to Map Spatial Gene Relationships and Dynamics in Tissues

Researchers have developed Gene SPatial Optimal Transport, or GeneSPOT, a new computational framework designed to characterize the spatial relationships among genes and quantify their reorganization across various biological conditions and over time. Published in Nature Methods, this gene-centric analytical framework complements existing cell-centric methods by mapping how the relational spatial organization of molecular features changes within tissues. While current spatial omics technologies primarily focus on identifying cellular states and differentially expressed molecular features, GeneSPOT extends this by evaluating spatial arrangements beyond individual cellular states. The framework has successfully resolved tissue structures in diverse applications, including validation analyses in the mouse brain, where it captured biologically meaningful spatial gene programs and identified organized molecular patterns within complex tissue architecture.
TrendlineTrendline
3billion and DeepLife Announce AI Drug Discovery Collaboration to Enhance Therapeutic Target Identification

3billion and DeepLife Announce AI Drug Discovery Collaboration to Enhance Therapeutic Target Identification

3billion and DeepLife Announce AI Drug Discovery Collaboration to Enhance Therapeutic Target Identification
TrendlineTrendline
Macrogen Launches Next-Generation Spatial Transcriptome Analysis Service in Asia

Macrogen Launches Next-Generation Spatial Transcriptome Analysis Service in Asia

Macrogen Launches Next-Generation Spatial Transcriptome Analysis Service in Asia
TrendlineTrendline
Illumina Inc. and Bruker Corporation Advance Spatial Omics Technology with New Offerings and Acquisitions

Illumina Inc. and Bruker Corporation Advance Spatial Omics Technology with New Offerings and Acquisitions

Illumina Inc. and Bruker Corporation Advance Spatial Omics Technology with New Offerings and Acquisitions
Rapid ReadRapid Read
Gates Foundation Awards £2 Million Grant to PhaSER Biomedical for Drug Development Acceleration

Gates Foundation Awards £2 Million Grant to PhaSER Biomedical for Drug Development Acceleration

PhaSER Biomedical, a biotech startup, has secured a £2 million grant from the Bill & Melinda Gates Foundation. This two-year renewal funding aims to advance drug discovery for neglected diseases by providing humanized mouse models. The grant will expand access to PhaSER’s 8HUM platform and related translational modeling, which are designed to improve preclinical prediction and reduce species-related failures in drug development. The 8HUM transgenic mouse models are engineered to mimic human drug-metabolizing pathways, offering more human-relevant pharmacokinetic and safety signals earlier in the development process. This is particularly crucial for diseases like tuberculosis, malaria, schistosomiasis, and Chagas disease, which often receive limited commercial investment. The funding also supports collaborative research efforts with global health researchers and the University of Dundee's Drug Discovery Unit.
Rapid ReadRapid Read
Roche Advances Next-Generation Sequencing in Asia Pacific with AXELIOS 1 Launch

Roche Advances Next-Generation Sequencing in Asia Pacific with AXELIOS 1 Launch

Roche is expanding its next-generation sequencing (NGS) initiatives in the Asia Pacific region following the global introduction of its AXELIOS 1 platform in June 2026. Building on initial adoption in South Korea, Roche plans to bring this advanced technology closer to researchers and laboratory leaders through 'AXELIOS Days' events scheduled for November in Sydney, Australia, and Seoul, South Korea. The AXELIOS 1 platform utilizes Roche's proprietary sequencing by expansion (SBX) technology, which is designed to offer flexibility and high performance across various sequencing workflows. This technology converts genetic information into synthetic molecules called Xpandomers, which are approximately 50 times longer than original DNA fragments, enhancing sequencing accuracy. The platform also boasts high-speed processing, capable of completing sequencing runs in approximately 15 minutes to four hours and generating at least 1.8 terabases in a four-hour run, with the potential for same-day whole-genome sequen...
Rapid ReadRapid Read
Machine Learning Uncovers Cell-Type Specific Alzheimer's Disease Programs

Machine Learning Uncovers Cell-Type Specific Alzheimer's Disease Programs

A new study utilizing single-cell machine learning has identified genetically anchored, cell-type specific programs related to Alzheimer's disease (AD). Researchers employed a supervised machine learning framework to predict AD status at the single-cell level, analyzing single-nucleus RNA-sequencing data from hundreds of donors. This approach revealed specific genes and pathways relevant to AD, including microglia-specific neuroinflammatory genes and genes involved in protein homeostasis and glycosylation across various cell types. The study also found that multiple identified candidates are already linked to existing pharmacologic compounds, such as EGFR and HSP90AA1, which have AD-relevant mechanisms. The research aimed to understand the molecular changes occurring in individual brain cells during the progression of Alzheimer's, providing a more granular view than previous studies.